2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
22
Neoplasm Metastasis
15
Carcinoma, Non-Small-Cell Lung
7
Glioblastoma
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Recurrence
4
Ovarian Neoplasms
4
Lymphoma, Mantle-Cell
4
Lymphoma, Follicular
4
Endometrial Neoplasms
4
Brain Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
3
Lung Neoplasms
3
Hereditary Sensory and Autonomic Neuropathies
3
Head and Neck Neoplasms
3
Solid Tumors
2
Melanoma
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Esophageal Neoplasms
2
Waldenstrom Macroglobulinemia
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Treatment for Metastatic or Locally Advanced Cervical Cancer
1
Tongue Neoplasms
1
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
NVP-BKM120
×
Clear all
NCT01737450
2019-06-24
PIK-ORL
Centre Leon Berard
Phase 2
Completed
58 enrolled